Exchange: NASDAQ·Updated 07:41 PM EDT

MIRM News

News
all
press releases
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.
Zacks
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.
Zacks
More News
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.
Zacks
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to hepatitis B surface antigen (HBsAg), for the...
Business Wire
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.
Stocktwits
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV...
Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older...
Business Wire
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.
Stocktwits
FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week
Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.
Stocktwits
MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains?
Mirum and Incyte are now awaiting the FDA’s decision on zilurgisertib, a once-a-day pill for an ultra-rare bone disease.
Stocktwits
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on September 10, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 28,512 shares of common stock and 37,375...
Business Wire

Advertisement|Remove ads.